Mirxes listed on the Hong Kong Stock Exchange Main Board on 23 May 2025, reaching a market capitalisation of HK$8.29 billion. It is the first Southeast Asian biotech company to achieve unicorn status upon listing on the exchange.

• Stock Performance: Shares HK$31.95 closed at HK$30.00 per share on the first day of trading, representing a 28.76% increase from the offer price, with an aggregate turnover of HK$275 million.
• Growth Strategy: The listing proceeds are intended to scale the market penetration of GASTROClear and support the development of a precision multi-omics clinical testing platform in Southeast Asia.
• Product Pipeline: Mirxes focuses on innovative miRNA-based solutions for early disease detection, led by its flagship molecular cancer screening product, GASTROClear. The company is currently leveraging its “end-to-end” R&D and manufacturing capabilities to expand its clinical testing platform across Southeast Asia.

This summary is based on a press release issued by Mirxes.